Chronic Kidney Disease Requiring Hemodialysis study: Super High-Flux Dialyzer vs High-Flux Dialyzer
Official title DIALysis With EXpanded Solute Removal
ClinicalTrials.gov ID: NCT06660277
What this study is testing
- What it's testing
- The study aims to find out if using a special dialysis filter that removes more waste from the blood reduces the risk of death compared to standard filters.
- Who it's for
- This study is looking for people who have kidney failure and already receive regular dialysis treatments.
- What's involved
- Participants will continue their regular dialysis schedule but will use either a special filter that removes more waste or a standard filter. No extra tests or visits are needed.
- Time commitment
- The study involves using the assigned filter during regular dialysis sessions, with data collected from medical records.
Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 45 and older
You may be able to join if
- Age 60 years or older; or
- Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and
- Receiving any form of dialysis regularly for the previous 90 days; and
- Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and
- A valid provincial or territorial health insurance card number.
You likely can't join if
- Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or
- Planned to receive HDF; or
- Planned to receive nocturnal HD; or
- Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney...
- Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or
- An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or
See the full eligibility criteria
- Age 60 years or older; or
- Age 45 to 59 years with a history of diabetes mellitus (Type 1 or Type 2) regardless of current glycemic status; and
- Receiving any form of dialysis regularly for the previous 90 days; and
- Currently receiving HD in-centre (main or satellite unit) 3 or more times per week; and
- A valid provincial or territorial health insurance card number.
- Known or anticipated intolerance to the Nipro Elisio HX dialyzer; or
- Planned to receive HDF; or
- Planned to receive nocturnal HD; or
- Anticipated to discontinue in-centre HD in the next 3 months for any reason (examples: palliation, transplantation, home dialysis, recovery of kidney function, death, others); or
- Anticipated severe non-adherence to the frequency or duration of prescribed dialysis treatment; or
- An overriding clinical preference for expanded HD (i.e., dialysis with the Elisio HX or other comparable dialyzer, such as Baxter TheranovaTM); or
- Another medical, psychosocial, or logistical reason; or
- Enrolled in another clinical trial that explicitly prohibits concurrent participation in other clinical trials or that would substantially interfere with adherence to the DIALEX procedures (note that DIALEX otherwise...
- Previously enrolled in this trial; or
- Declined participation.
The study team makes the final eligibility decision.
Where it is enrolling
- London, Ontario, Canada
- Orillia, Ontario, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 45 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at London, Ontario, Canada; Orillia, Ontario, Canada. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.